Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Articles|August 1, 2019

BioPharm International

  • BioPharm International-08-01-2019
  • Volume 32
  • Issue 8

Plate Reader Offers Real-Time Detection and Analysis

Tecan’s Spark Cyto cell plate reader offers real-time detection and analysis of biological, chemical, and physical events while consistently capturing the maximum amount of data from every well.

Tecan’s Spark Cyto cell plate reader offers real-time detection and analysis of biological, chemical, and physical events while consistently capturing the maximum amount of data from every well.

The device combines the flexibility of a high-end multimode plate reader with whole well imaging and comprehensive environmental control for cell-based assays. Capable camera components and a patent-pending LED autofocus system provide real-time data acquisition and analysis for 6- to 384-well formats.

The reader allows qualitative and quantitative information to be integrated into multiparametric data sets, delivering insights faster than previously available, the company states. With three magnification levels and four acquisition channels, the device enables entire cell populations to be investigated by capturing the whole well area of 96- or 384-well microplates in just one image without tiling or distortion.

Tecan

 


Related to this article

The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron and Alnylam’s cemdisiran (Livsayis) as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.
The BioPharm Brief: A First for Streamlined Biosimilar Approval, a Head-to-Head Bispecific Trial in Wet AMD, and In Vivo KIR-CAR T
Biocon’s pertuzumab biosimilar Pebrilzo becomes the first biosimilar approved under EMA’s tailored clinical approach, Visara doses the first patient in a phase 2b trial comparing its VEGF-A/ANG-2 bispecific VIS-101 with aflibercept in wet AMD, and Verismo Therapeutics licenses Stanford’s PACK-IT technology for in vivo KIR-CAR T therapies.